# Apellis Pharmaceuticals, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Apellis Pharmaceuticals, Inc.).

## Overview

Apellis Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company built around complement inhibition, with pegcetacoplan as its core molecule. The company markets SYFOVRE for geographic atrophy secondary to age-related macular degeneration and EMPAVELI for paroxysmal nocturnal hemoglobinuria, with newer approvals expanding EMPAVELI into rare kidney diseases. Its business combines U.S. product commercialization with selective ex-U.S. partnering, most notably through Sobi for Aspaveli outside the United States. Apellis also continues to invest in pipeline programs that extend its complement biology platform into additional high-unmet-need diseases.

## Products & services

• SYFOVRE (pegcetacoplan injection) for geographic atrophy
• EMPAVELI (pegcetacoplan) for PNH, C3G and IC-MPGN
• Ex-U.S. licensed Aspaveli commercialization via Sobi
• Pegcetacoplan development for additional indications
• Complement-system R&D and clinical development programs

- **Commercial ophthalmology** (44%) — Intravitreal pegcetacoplan sold as SYFOVRE for geographic atrophy secondary to AMD.
- **Commercial rare disease hematology/nephrology** (13%) — Systemic pegcetacoplan sold as EMPAVELI for PNH and newly approved kidney indications.
- **Licensing and collaboration revenue** (7%) — Product supply and royalty revenue from the Sobi collaboration outside the U.S.
- **Pipeline development** (36%) — Preclinical and clinical programs extending complement inhibition into new diseases.

- SYFOVRE (pegcetacoplan injection) for geographic atrophy
- EMPAVELI (pegcetacoplan) for PNH, C3G and IC-MPGN
- Ex-U.S. licensed Aspaveli commercialization via Sobi
- Pegcetacoplan development for additional indications
- Complement-system R&D and clinical development programs

## Customers

Apellis sells primarily to U.S. specialty physicians and the patients they treat, rather than to broad retail consumers. SYFOVRE is used by retina specialists treating geographic atrophy, while EMPAVELI is prescribed by hematologists and nephrologists for rare complement-mediated diseases such as PNH, C3G and IC-MPGN. The company also serves specialty pharmacies, specialty distributors, payors and reimbursement intermediaries that are central to access and uptake in these high-cost therapies. Outside the United States, Apellis monetizes its platform through Sobi, which buys product and pays royalties under the collaboration agreement.

- **Retina specialists and GA patients** (primary) — They use SYFOVRE to slow progression in geographic atrophy, a chronic ophthalmology market with concentrated prescribers and reimbursement sensitivity.
- **Hematology patients with PNH** (primary) — They buy EMPAVELI through treating physicians to control complement-driven hemolysis in a rare disease setting.
- **Nephrology patients with C3G and IC-MPGN** (secondary) — They use EMPAVELI for newly approved kidney indications where specialist diagnosis and access pathways are critical.
- **Specialty pharmacies and distributors** (primary) — They purchase and distribute product within the U.S. specialty channel and are important to inventory flow, returns and rebates.
- **Sobi collaboration partner** (secondary) — Sobi buys product and commercializes Aspaveli outside the U.S., generating supply and royalty revenue for Apellis.

- Retina specialists treating geographic atrophy patients with SYFOVRE
- Hematologists treating PNH patients with EMPAVELI
- Nephrologists treating C3G and IC-MPGN patients with EMPAVELI
- Specialty pharmacies and specialty distributors handling channel access
- Payors and reimbursement decision-makers affecting patient uptake
- Sobi as ex-U.S. partner buying product and paying royalties

## Geography

Apellis is operationally centered in the United States, where it recognizes product revenue from EMPAVELI and SYFOVRE sales and maintains its commercial infrastructure. The company retains U.S. commercialization rights for systemic pegcetacoplan and worldwide rights for intravitreal pegcetacoplan, but ex-U.S. monetization is partly handled through Sobi. Europe is strategically important because Aspaveli has European approval and generates collaboration revenue, including product supply and royalties. The business therefore has a U.S.-heavy revenue base with a smaller but meaningful international licensing footprint tied to regulatory approvals and partner execution.

- **United States** (93%) — Estimated from disclosure that product revenue is derived from U.S. sales; remaining revenue is collaboration-related ex-U.S.
- **Europe** (7%) — Estimated from Sobi collaboration revenue and European commercialization of Aspaveli

- United States is the core commercial market for both marketed products
- U.S. sales drive product revenue for SYFOVRE and EMPAVELI
- Europe matters through Sobi's Aspaveli commercialization and royalties
- Ex-U.S. access depends on partner execution and local approvals
- Commercial infrastructure is built primarily for the U.S. specialty channel

## Strategy

Apellis is focused on maximizing the commercial opportunity for its two marketed pegcetacoplan products while broadening the label and geographic reach of the platform. Near term, the company is prioritizing U.S. commercialization of SYFOVRE and EMPAVELI, including market access, disease education, patient support and distribution execution. It is also pursuing additional approvals for EMPAVELI in rare kidney diseases and building the infrastructure needed to support future indications. Longer term, Apellis wants to extend complement inhibition into new programs, including partnered and internally developed pipeline assets, to reduce dependence on a small number of products.

- **Grow SYFOVRE commercial uptake** (short-term) — SYFOVRE is the largest commercial opportunity and requires continued market education and reimbursement execution in a concentrated retina market.
- **Expand EMPAVELI into additional indications** (medium-term) — New approvals in C3G and IC-MPGN broaden the addressable rare disease market and diversify revenue beyond PNH.
- **Advance pipeline beyond pegcetacoplan** (long-term) — A broader pipeline reduces concentration risk and supports long-term growth if current products mature or face competition.

- Expand SYFOVRE adoption in geographic atrophy
- Defend and grow EMPAVELI in PNH and new rare disease indications
- Build U.S. specialty sales, access and patient support capabilities
- Pursue ex-U.S. commercialization through partners where efficient
- Advance pipeline programs beyond pegcetacoplan
- Use complement biology as a platform across multiple diseases

## Risks

Apellis remains exposed to the commercial risk of relying on a small number of products, especially SYFOVRE and EMPAVELI, so any slowdown in uptake, pricing pressure or competitive displacement would have an outsized effect. The company also faces execution risk in specialty commercialization because its products depend on concentrated prescribers, payor access, patient support and third-party distribution. Manufacturing and supply-chain dependence on a limited number of contract manufacturers creates operational vulnerability if a supplier is delayed, unavailable or underperforms. As a biotech company, Apellis also carries the usual clinical, regulatory and reimbursement risks, including the possibility that future indications or pipeline programs do not achieve approval or broad adoption.

- **Dependence on a small number of products** [high] — Most revenue is tied to SYFOVRE and EMPAVELI, so any safety issue, slower uptake or label setback would materially affect results.
- **Competitive pressure in rare disease markets** [high] — EMPAVELI faces competition from oral and other therapies, which can reduce demand and pricing power.
- **Third-party manufacturing and supply disruption** [high] — The company relies on a small number of contract manufacturers for active ingredient and finished product supply.
- **Reimbursement and rebate pressure** [medium] — Specialty drugs require payor access and can see higher rebates, returns and channel deductions that reduce net revenue.
- **Pipeline and regulatory failure** [medium] — Future growth depends on approvals and clinical success in new indications and programs, which are inherently uncertain.

- Concentration in two marketed products creates revenue dependence
- Competitive pressure can reduce uptake, especially for EMPAVELI
- Specialty payor and rebate dynamics can pressure net pricing
- Third-party manufacturers and distributors are critical to supply
- Regulatory and clinical trial outcomes remain uncertain for pipeline assets
- Commercial execution in rare disease and ophthalmology is complex

## Accounting

Apellis' most important accounting judgments are centered on product revenue, where net sales are reduced by estimates for returns, rebates and other variable consideration. Because SYFOVRE and EMPAVELI are sold through specialty channels, management must estimate channel inventory, sell-through, GPO rebate tiers and other deductions, and changes in those estimates can move revenue between periods. The company also recognizes collaboration revenue from Sobi, including product supplied and royalties, which depends on contract terms and the timing of partner purchases and sales. In addition, inventory and accrued R&D expenses are significant estimates because the company relies on third-party manufacturers and continues to invest in clinical development, making quarter-to-quarter results sensitive to supply timing and commercialization activity.

- **Revenue recognition and variable consideration** — Can shift revenue between periods if estimates change
- **Specialty channel reserves** — Affects net sales and gross-to-net deductions
- **Collaboration revenue from Sobi** — Creates timing variability in licensing and other revenue
- **Inventory and accrued R&D estimates** — Can affect cost of sales, operating expenses and working capital

- Net product revenue is reduced by returns and rebate estimates
- Specialty channel inventory affects revenue reserve assumptions
- Sobi collaboration revenue depends on supply and royalty timing
- Inventory valuation matters because of third-party manufacturing
- Accrued R&D expenses reflect ongoing development and trial activity
- Quarterly revenue can fluctuate with partner purchase timing and rebates

---

*Last updated: 2026-08-11T04:46:21.025386+00:00*